Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GPCR |
---|---|---|
09:32 ET | 4327 | 37.12 |
09:34 ET | 150 | 37.32 |
09:38 ET | 100 | 37.12 |
09:39 ET | 128 | 37.47 |
09:48 ET | 1275 | 37.46 |
09:50 ET | 4419 | 37.95 |
09:52 ET | 3720 | 37.7 |
09:54 ET | 800 | 37.6 |
09:56 ET | 1400 | 37.545 |
09:57 ET | 1610 | 37.61 |
09:59 ET | 2580 | 37.56 |
10:01 ET | 4645 | 37.61 |
10:03 ET | 9427 | 37.68 |
10:06 ET | 10417 | 37.79 |
10:08 ET | 2877 | 37.9 |
10:10 ET | 1018 | 37.81 |
10:12 ET | 1053 | 37.83 |
10:14 ET | 3445 | 37.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Structure Therapeutics Inc | 2.1B | -16.3x | --- |
Vera Therapeutics Inc | 2.1B | -17.1x | --- |
Janux Therapeutics Inc | 2.2B | -46.1x | --- |
Verona Pharma PLC | 2.2B | -17.7x | --- |
CG Oncology Inc | 2.3B | -30.8x | --- |
Celldex Therapeutics Inc | 2.3B | -12.6x | --- |
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.32 |
Book Value | $9.76 |
P/E Ratio | -16.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.